

Roberto S Accolla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8375041/publications.pdf>

Version: 2024-02-01

145
papers

3,934
citations

136740

32
h-index

138251

58
g-index

150
all docs

150
docs citations

150
times ranked

3611
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Trends in Immunology, 1981, 2, 239-249.	7.5	344
2	Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28 ^{hi} T cells and inhibit both T-Cell proliferation and CTL function. Human Immunology, 2004, 65, 142-156.	1.2	151
3	Subsets of human Ia-like molecules defined by monoclonal antibodies. Molecular Immunology, 1981, 18, 403-411.	1.0	149
4	Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class II isotypes. European Journal of Immunology, 1989, 19, 2171-2174.	1.6	124
5	Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, 2017, 137, 41-48.	1.9	116
6	Distinct HLA-DR epitopes and distinct families of HLA-DR molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-I-A crossreacting with human DR molecule. I. Cross-inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb. European Journal of Immunology, 1983, 13, 106-111.	1.6	111
7	The genes for tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse. Nucleic Acids Research, 1986, 14, 7713-7725.	6.5	108
8	Isolation of distinct cDNA clones encoding HLA-DR beta chains by use of an expression assay.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 7465-7469.	3.3	105
9	CELL lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. International Journal of Cancer, 1991, 47, 20-25.	2.3	100
10	Isolation of cDNA clones encoding HLA-DR alpha chains.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 6979-6983.	3.3	97
11	Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune Response. PLoS ONE, 2012, 7, e39170.	1.1	95
12	Targeted Delivery of Tumor Necrosis Factor- α to Tumor Vessels Induces a Therapeutic T Cell-Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin. Clinical Cancer Research, 2006, 12, 2575-2582.	3.2	85
13	CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory. Clinical Cancer Research, 2006, 12, 3435-3443.	3.2	79
14	Down syndrome, autoimmunity and T regulatory cells. Clinical and Experimental Immunology, 2012, 169, 238-243.	1.1	78
15	Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. European Journal of Immunology, 2003, 33, 1183-1192.	1.6	73
16	Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. International Journal of Cancer, 1994, 57, 167-171.	2.3	72
17	Tat Protein Is an HIV-1-Encoded β -Chemokine Homolog That Promotes Migration and Up-Regulates CCR3 Expression on Human Fc γ RI+ Cells. Journal of Immunology, 2000, 165, 7171-7179.	0.4	67
18	CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine. Frontiers in Immunology, 2019, 10, 1806.	2.2	63

#	ARTICLE	IF	CITATIONS
19	Ia-negative B-cell variants reveal a coordinate regulation in the transcription of the HLA Class II gene family. <i>Immunogenetics</i> , 1984, 19, 349-353.	1.2	57
20	Active suppression of major histocompatibility complex class II gene expression during differentiation from B cells to plasma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 2229-2233.	3.3	57
21	Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody. <i>European Journal of Immunology</i> , 1981, 11, 721-726.	1.6	56
22	APC gene mutations and allelic losses in sporadic ampullary tumours: Evidence of genetic difference from tumours associated with familial adenomatous polyposis. <i>Journal of Cellular Biochemistry</i> , 1996, 68, 305-312.		55
23	ras-family gene mutations in neoplasia of the ampulla of Vater. <i>International Journal of Cancer</i> , 1994, 59, 39-42.	2.3	53
24	Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNF- α . <i>International Journal of Cancer</i> , 2010, 127, 101-110.	2.3	50
25	Somatic cell hybrids producing antibodies specific to human fibronectin. <i>International Journal of Cancer</i> , 1980, 25, 325-329.	2.3	46
26	NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. <i>International Immunology</i> , 2009, 21, 599-606.	1.8	46
27	Demonstration at the single-cell level of the existence of distinct clusters of epitopes in two predefined human Ia molecular subsets. <i>European Journal of Immunology</i> , 1982, 12, 166-169.	1.6	44
28	231 The MHC Class II Transactivator, CIITA, is a Viral Restriction Factor for Human Oncogenic Retroviruses. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 100.	0.9	43
29	Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12. <i>Immunogenetics</i> , 1992, 36, 117-120.	1.2	42
30	Therapy-induced antitumor vaccination by targeting tumor necrosis factor- α to tumor vessels in combination with melphalan. <i>European Journal of Immunology</i> , 2007, 37, 3381-3392.	1.6	41
31	The MHC class II transactivator: prey and hunter in infectious diseases. <i>Trends in Immunology</i> , 2001, 22, 560-563.	2.9	40
32	Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State. <i>Frontiers in Oncology</i> , 2014, 4, 32.	1.3	40
33	Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005285.	1.3	35
34	Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. <i>Retrovirology</i> , 2015, 12, 59.	0.9	34
35	Human adipose-derived stem cells promote vascularization of collagen-based scaffolds transplanted into nude mice. <i>Regenerative Medicine</i> , 2016, 11, 261-271.	0.8	34
36	HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases. <i>Frontiers in Microbiology</i> , 2017, 8, 2615.	1.5	34

#	ARTICLE	IF	CITATIONS
37	Monoclonal antibodies against carcinoembryonic antigen (CEA) used in a solid-phase enzyme immunoassay. First clinical results. <i>Journal of Immunological Methods</i> , 1982, 49, 129-139.	0.6	32
38	The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication. <i>European Journal of Immunology</i> , 2002, 32, 2783-2791.	1.6	32
39	Major Histocompatibility Complex Class II Transactivator CIITA Is a Viral Restriction Factor That Targets Human T-Cell Lymphotropic Virus Type 1 Tax-1 Function and Inhibits Viral Replication. <i>Journal of Virology</i> , 2011, 85, 10719-10729.	1.5	31
40	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	3.2	31
41	Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells. <i>European Journal of Immunology</i> , 1996, 26, 2456-2460.	1.6	30
42	Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes. <i>BMC Microbiology</i> , 2005, 5, 20.	1.3	30
43	The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF- κ B by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein. <i>Journal of Virology</i> , 2016, 90, 3708-3721.	1.5	30
44	Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR. <i>European Journal of Immunology</i> , 2000, 30, 1120-1126.	1.6	29
45	CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4 ⁺ TH cells <i>in vivo</i> and vaccinate the host against parental MHC-II-negative tumor cells. <i>Oncolmmunology</i> , 2017, 6, e1261777.	2.1	29
46	Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4 ⁺ T cell priming and CD8 ⁺ T cell effector functions. <i>International Immunology</i> , 2009, 21, 655-665.	1.8	28
47	CIITA-driven MHC class II positive tumor cells: Preventive vaccines and superior generators of antitumor CD4 ⁺ T lymphocytes for immunotherapy. <i>International Journal of Cancer</i> , 2010, 127, 1614-1624.	2.3	28
48	Optimal MHC-II-restricted tumor antigen presentation to CD4 ⁺ T helper cells: the key issue for development of anti-tumor vaccines. <i>Journal of Translational Medicine</i> , 2012, 10, 154.	1.8	28
49	MHC: orchestrating the immune response. <i>Trends in Immunology</i> , 1995, 16, 8-11.	7.5	26
50	Different levels of control prevent interferon- γ -inducible HLA-class II expression in human neuroblastoma cells. <i>Oncogene</i> , 2003, 22, 7848-7857.	2.6	26
51	HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines. <i>European Journal of Immunology</i> , 2000, 30, 19-28.	1.6	25
52	Structural analysis of the CD69 early activation antigen by two monoclonal antibodies directed to different epitopes. <i>Molecular Immunology</i> , 1991, 28, 159-168.	1.0	24
53	The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2. <i>Blood</i> , 2004, 103, 995-1001.	0.6	24
54	CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches. <i>Oncolmmunology</i> , 2019, 8, 1548243.	2.1	24

#	ARTICLE	IF	CITATIONS
55	Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization. <i>Scientific Reports</i> , 2018, 8, 14249.	1.6	23
56	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. <i>European Journal of Immunology</i> , 1999, 29, 499-511.	1.6	22
57	HTLV-1 HBZ Protein Resides Exclusively in the Cytoplasm of Infected Cells in Asymptomatic Carriers and HAM/TSP Patients. <i>Frontiers in Microbiology</i> , 2019, 10, 819.	1.5	22
58	CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100032.	2.5	22
59	Antibody-mediated activation of a deletion-mutant β -galactosidase defective in the β region. <i>FEBS Letters</i> , 1976, 67, 299-302.	1.3	21
60	Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen (CEA). <i>Immunology Letters</i> , 1982, 5, 85-91.	1.1	21
61	The importance of cross-reactions between species: Mouse allo-anti-Ia monoclonal antibodies as a powerful tool to define human Ia subsets. <i>Human Immunology</i> , 1983, 8, 75-82.	1.2	21
62	Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12861-12866.	3.3	21
63	The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells. <i>Journal of Translational Medicine</i> , 2016, 14, 94.	1.8	20
64	Block of Stat-1 activation in macrophages phagocytosing bacteria causes reduced transcription of CIITA and consequent impaired antigen presentation. <i>European Journal of Immunology</i> , 2002, 32, 1309.	1.6	19
65	The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for insulin-dependent diabetes mellitus. <i>Molecular Immunology</i> , 1994, 31, 429-437.	1.0	16
66	The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators. <i>Frontiers in Microbiology</i> , 2013, 4, 234.	1.5	16
67	Tumor Immunology meets Immunology: Modified cancer cells as professional APC for priming naïve tumor-specific CD4+ T cells. <i>Oncotarget</i> , 2017, 6, e1356149.	2.1	16
68	Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1. <i>Frontiers in Immunology</i> , 2017, 8, 564.	2.2	16
69	Epigenetic silencing of HTLV-1 expression by the HBZ RNA through interference with the basal transcription machinery. <i>Blood Advances</i> , 2020, 4, 5574-5579.	2.5	16
70	Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response. <i>Pancreas</i> , 2014, 43, 1066-1072.	0.5	14
71	Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1. <i>Retrovirology</i> , 2019, 16, 34.	0.9	14
72	The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells. <i>European Journal of Immunology</i> , 2005, 35, 603-611.	1.6	13

#	ARTICLE	IF	CITATIONS
73	Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN- γ in promyelocytic cells. <i>International Immunology</i> , 2008, 20, 1457-1466.	1.8	13
74	Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication. <i>Journal of Translational Medicine</i> , 2011, 9, 106.	1.8	13
75	In vivo modification of major histocompatibility complex class II DRA promoter occupancy mediated by the AIR-1 trans-activator. <i>European Journal of Immunology</i> , 1994, 24, 2415-2420.	1.6	12
76	Double-stranded deoxyribonucleic acid binds to HLA class II molecules and inhibits HLA class II-mediated antigen presentation. <i>European Journal of Immunology</i> , 1998, 28, 3968-3979.	1.6	12
77	Identification of Immunodominant Epitopes in Inactivated Tat-Vaccinated Healthy and HIV-1 "Infected Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 47-55.	0.9	12
78	Experimental therapeutic approaches to adenocarcinoma: The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer. <i>Surgical Oncology</i> , 2007, 16, 33-36.	0.8	12
79	Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T cell leukemia. <i>Haematologica</i> , 2021, 106, 2076-2085.	1.7	12
80	HLA-DQB1 typing of north east Italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-enzyme immunoassay (DEIA). <i>Molecular Immunology</i> , 1993, 30, 69-76.	1.0	11
81	Human T-Cell Leukemia Virus Type II Directly Acts on CD34+ Hematopoietic Precursors by Increasing Their Survival Potential. Envelope-Associated HLA Class II Molecules Reverse This Effect. <i>Blood</i> , 1998, 91, 2296-2304.	0.6	11
82	Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 28-36.	2.1	10
83	Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines. <i>Virus Research</i> , 2019, 269, 197631.	1.1	10
84	Host Defense Mechanisms against Pathogens. <i>Surgical Infections</i> , 2006, 7, s-5-s-7.	0.7	9
85	Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells. <i>Cancers</i> , 2020, 12, 3181.	1.7	9
86	The dual function of the MHC class II transactivator CIITA against HTLV retroviruses. <i>Frontiers in Bioscience</i> , 2009, 14, 4149-56.	0.8	9
87	Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses. <i>Frontiers in Immunology</i> , 2017, 8, 1362.	2.2	8
88	A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes. <i>Immunologic Research</i> , 1990, 9, 20-33.	1.3	7
89	Analysis of the antigen specific T cell repertoires in HIV infection. <i>Immunology Letters</i> , 2001, 79, 85-91.	1.1	7
90	HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3135-TPS3135.	0.8	7

#	ARTICLE	IF	CITATIONS
91	Editorial: Novel Strategies for Anti-Tumor Vaccines. <i>Frontiers in Immunology</i> , 2019, 10, 3117.	2.2	7
92	Physiologic target of the Air-1 trans-activator revealed by stable transfection assay. <i>Immunogenetics</i> , 1994, 39, 8-14.	1.2	6
93	Typing of a Polymorphic Human Gene Conferring Susceptibility to Insulin-Dependent Diabetes Mellitus by Picosecond-Resolved FRET on Non-Purified/Non-Amplified Genomic DNA. <i>DNA Research</i> , 2012, 19, 347-355.	1.5	6
94	Molecular genotyping of the HLA-DQ ? gene region. <i>Immunogenetics</i> , 1988, 27, 12-18.	1.2	5
95	Human Naive CD4 T-Cell Clones Specific for HIV Envelope Persist for Years In Vivo in the Absence of Antigenic Challenge. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 132-139.	0.9	5
96	Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma. <i>Cancer Research</i> , 2020, 80, LB-094-LB-094.	0.4	5
97	MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle. <i>Microbes and Infection</i> , 1999, 1, 871-877.	1.0	4
98	MHC immunoevasins: protecting the pathogen reservoir in infection. <i>Tissue Antigens</i> , 2005, 66, 2-8.	1.0	4
99	Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human. <i>European Journal of Immunology</i> , 1996, 26, 259-262.	1.6	3
100	Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells. <i>Journal of Translational Medicine</i> , 2018, 16, 64.	1.8	3
101	Investigating Human T Cell Lymphotropic Retrovirus (HTLV) Tax Function with Molecular and Immunophenotypic Techniques. <i>Methods in Molecular Biology</i> , 2014, 1087, 299-313.	0.4	3
102	Unsung Hero Robert C. Gallo. <i>Science</i> , 2009, 323, 206-207.	6.0	2
103	New Strategies of Mammary Cancer Vaccination. <i>Breast Journal</i> , 2010, 16, S42-S44.	0.4	2
104	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. <i>European Journal of Immunology</i> , 1999, 29, 499-511.	1.6	2
105	Superinfection by Epstein-Barr virus of a subset of Raji cells is independent of HLA class-II antigens. <i>International Journal of Cancer</i> , 1990, 45, 989-989.	2.3	1
106	Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen. <i>Immunogenetics</i> , 1994, 40, 217-221.	1.2	1
107	Time-Resolved Frster Resonance Energy Transfer Analysis of Single-Nucleotide Polymorphisms: Towards Molecular Typing of Genes on Non-Purified and Non-PCR-Amplified DNA. <i>Journal of Molecular Biology Research</i> , 2013, 3, .	0.1	1
108	The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1. <i>Retrovirology</i> , 2015, 12, .	0.9	1

#	ARTICLE	IF	CITATIONS
109	P-D2 TRIM22 binds to CIITA and sequesters it into nuclear bodies containing TRIM19/PML and Cyclin T1: Implications for HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 59-59.	0.9	1
110	D-105 Reversible HIV-1 Latency Induced in Primary Human Monocyte-Derived Macrophages by Repeated M1 Polarization. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 40-40.	0.9	1
111	Abstract 2354: Cancer vaccine development for hepatocellular carcinoma - HEPAVAC. <i>Cancer Research</i> , 2016, 76, 2354-2354.	0.4	1
112	Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes. <i>PLoS ONE</i> , 2018, 13, e0190869.	1.1	1
113	Monoclonal Antibodies as a Tool to Detect Melanoma-Associated Antigens. , 1982, , 53-73.		1
114	Human T-Cell Leukemia Virus Type II Directly Acts on CD34+ Hematopoietic Precursors by Increasing Their Survival Potential. Envelope-Associated HLA Class II Molecules Reverse This Effect. <i>Blood</i> , 1998, 91, 2296-2304.	0.6	1
115	Biochemical aspects of human Ia molecules. <i>Human Immunology</i> , 1983, 8, 41-43.	1.2	0
116	The MHC Class II Transactivator (CIITA): A "Physiologic" Drug Against HIV-1 Replication. <i>Retrovirology</i> , 2005, 2, P2.	0.9	0
117	Title is missing!. <i>Retrovirology</i> , 2005, 2, S55.	0.9	0
118	The MHC Class II Transactivator (CIITA): A Physiologic Inhibitor of HTLV-2 Retroviral Infection. <i>Retrovirology</i> , 2005, 2, P5.	0.9	0
119	A dual defensive role of CIITA against retroviral infections. <i>Retrovirology</i> , 2006, 3, S102.	0.9	0
120	153 Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 51, .	0.9	0
121	202 The MHC Class II Transactivator CIITA, a Restriction Factor for Human Retroviruses and a Molecule Making the Bridge Between Adaptive and Intrinsic Immunity. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 86.	0.9	0
122	136 HTLV-2 Tax-2 Transactivator Increases the Expression and the Function of its Inhibitor CIITA, the Master Regulator of HLA-II Gene Transcription. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 55.	0.9	0
123	The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T-Cell Lymphotropic Virus Type 1. <i>Retrovirology</i> , 2011, 8, .	0.9	0
124	MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to, and affecting Tax-2 intracellular localization. <i>Retrovirology</i> , 2011, 8, A172.	0.9	0
125	E1 Molecular and Cellular Correlates of the CIITA-Mediated Inhibition of HTLV-2 Tax-2 Transactivator Function Resulting in Loss of Viral Replication. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 82.	0.9	0
126	E2 The MHC-II Transactivator CIITA, a Viral Restriction Factor Targeting Human T-Cell Lymphotropic Virus Type 1 Tax-1 Function and Inhibiting Viral Replication. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 82.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes. Proceedings of SPIE, 2012, , .	0.8	0
128	P105â€fThe MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 73.	0.9	0
129	P104â€fSuitable Antigen Availability. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 72.	0.9	0
130	P101â€fThe MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kBactivation. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 71.	0.9	0
131	The MHC Class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation. Retrovirology, 2014, 11, P64.	0.9	0
132	Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. Retrovirology, 2015, 12, .	0.9	0
133	Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. Retrovirology, 2015, 12, .	0.9	0
134	B-104 Cancer vaccine: Tumor immunology meets...Immunology. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 36-36.	0.9	0
135	A-104â€fTracing the intracellular journey of HTLV-1 HBZ during infection: From asymptomatic carriers to HAM/TSP ending to ATL: A one-way ticket?. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 32-32.	0.9	0
136	HTLV-1 Infection and Adult T Cell Leukemia Mechanisms of Oncogenesis and Alteration of Immunity. , 2021, , .		0
137	The AIR-1 encoded class II transactivator (CIITA): the master coordinator of MHC class II gene expression and ..more. Advances in Experimental Medicine and Biology, 2001, 495, 83-91.	0.8	0
138	224 The MHC-II Transactivator, CIITA, Inhibits Tat-Mediated HIV-1 LTR Transactivation and Virus Replication in Human U937 Monocytic Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 97.	0.9	0
139	Role of the HLA-DQ Genotype in IDDM Susceptibility. Medical Science Symposia Series, 1994, , 21-26.	0.0	0
140	Abstract B048: The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein. , 2016, , .		0
141	Abstract B047: Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment. , 2016, , .		0
142	Abstract A115: Cancer vaccine development for hepatocellular carcinoma â€“ HEPAVAC. , 2016, , .		0
143	Abstract A014: CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity. , 2016, , .		0
144	Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAJuvantÂ®): HEPAVAC. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
145	The Road to HTLV-1-Induced Leukemia by Following the Subcellular Localization of HTLV-1-Encoded HBZ Protein. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0